Anti-NMDA receptor encephalitis medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] AE Dheeraj Makkar, M.D.[2]
Overview
The treatment of anti-NMDAR encephalitis involves immunotherapy, tumor diagnosis, and excision. Early immunotherapy has shown to improve outcomes. Treatment options include corticosteroids, plasmapheresis, immunoglobulins, and rituximab.
Medical Therapy
The treatment of anti-NMDAR encephalitis should include immunotherapy and the diagnosis and excision of the tumor. There is evidence that early immunotherapy may result in quicker recovery and decreased mortality.
Current immunotherapy includes corticosteroids, immune plasmapheresis, intravenous immunoglobulins, and rituximab.
References
[1] [2] Template:WH Template:WS
- ↑ Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M; et al. (2008). “Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies”. Lancet Neurol. 7 (12): 1091–8. doi:10.1016/S1474-4422(08)70224-2. PMC 2607118. PMID 18851928.
- ↑ Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L; et al. (2013). “Late-onset anti-NMDA receptor encephalitis”. Neurology. 81 (12): 1058–63. doi:10.1212/WNL.0b013e3182a4a49c. PMC 3795591. PMID 23946310.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH